Premarket movers are typically beneficial to traders and investors since they provide a preview of what the market may do in the future. Traders can trade pre-market movers using either electronic communication networks (ECNs) or alternative trading systems (ATSs). Pre-market movers have huge bid-ask spreads due to limited liquidity and volume. Many retail brokers provide stock pre-market movements, but many have limits on the sorts of orders they accept.
Here are five pre-market movers that you might be interested in.
Ardelyx Inc. (ARDX)
Ardelyx Inc. (ARDX) shares were rising 80.33% to trade at $2.20 in pre-market at the last check. ARDX’s stock gained 0.82% to close Wednesday’s session at $1.23. The stock volume remained at 0.32 million shares, which was lower than the average daily volume of 4.12 million shares within the past 50 days. ARDX shares have risen by 17.14% over the last 12 months, and they have moved down by 0.00% in the past week. Over the past three months, the stock has gained 16.04%, while over the past six months, it has shed 86.99%. Further, the company has a current market of $234.29 million and its outstanding shares stood at 187.46 million.
DEEP TRACK CAPITAL LP bought a fresh place in Ardelyx Inc. (NASDAQ: ARDX). The institutional investor bought 14.3 million shares of the stock in a transaction that took place on 9/02/2022. In another most recent transaction, which was held on 9/30/2022, DAVID M. KNOTT PARTNERSHIP bought approximately 650.0 thousand shares of Ardelyx Inc. In a separate transaction that took place on 9/30/2022, the institutional investor, ASSENAGON ASSET MANAGEMENT SA (G bought 254.8 thousand shares of the company’s stock. The total Institutional investors and hedge funds own 29.00% of the company’s stock.
Cuentas Inc. (CUEN)
Cuentas Inc. (CUEN) has advanced 40.00% at $0.35 in pre-market trading hours on the last check Thursday. The stock of CUEN lost -28.00% to complete the last trading session at $0.25. The price range of the company’s shares was between $0.2498 and $0.3944. It traded 4.09 million shares, which was above its daily average of 0.26 million shares over 100 days. CUEN’s shares have dropped by -20.51% in the last five days, while they have subtracted -41.85% in the last month. Further, it is currently trading at a price-to-book ratio of 0.96.
Focusing on the company’s market volatility shows that it has a 1-Week Volatility index of 27.31%, and 14.79% for the month. This stock’s Average True Range (ATR) currently stands at 0.06, with the beta factor poised at 0.61. The indicator of Volatility helps exhibit the extent to which a stock is likely to plummet or climb when the rest of the market also dips or surges. If a stock has a beta score above 1, then its rate of volatility is high. Figures lower than 1, therefore, mean that the stock’s volatility at that particular moment is low.
Clearside Biomedical Inc. (CLSD)
At last check in pre-market trading, shares of Clearside Biomedical Inc. (CLSD) were up 31.11% at $1.77. CLSD’s stock closed the last session at $1.35, decreasing -4.26% or -$0.06. Shares of the company fluctuated between $1.32 and $1.44 throughout the day. The number of shares exchanged was 0.11 million, less than the company’s 50-day daily volume of 0.19 million and lower than its Year-to-date volume of 0.44 million. In the past 12 months, the company’s stock has advanced -71.09%, and in the last one week, the stock has moved up 5.47%. For the last six months, the stock has lost a total of -8.78%, and over the last three months, the stock has decreased by -10.00%. The stock has returned -50.91% so far this year.
Wedbush rated the Clearside Biomedical Inc. (NASDAQ: CLSD) stock “an Outperform”, with the firm’s price target at $19-$9. Wedbush’s estimates were contained in a research note released on Wednesday, December 15, 2021. Several other experts on Wall Street have posted such reports regarding the CLSD shares. According to H.C. Wainwright, the stock is “a Buy,”$10. H.C. Wainwright published their figures in a research note released to investors on Thursday, July 29, 2021. Other experts at ROTH Capital have the stock’s price target at $8 price; with their rating of the stock as “a Buy.”. These scores were published in a research note the firm released on Wednesday, May 13, 2020.
Elevate Credit Inc. (ELVT)
Elevate Credit Inc. (ELVT) shares have gained 66.04% at $1.76 in Thursday’s premarket session. Elevate Credit Inc.’s stock subtracted 0.00% to finish the last trading session at $1.06. The stock recorded a trading volume of 1.22 million shares, which is below the average daily trading volume published for the last 50 days of 0.15 million shares. The shares of Elevate Credit Inc. have retreated 10.42% in the last five days; however, they have gained 3.92% over the last month. The stock price has shed -44.21% over the last three months and has lost -69.36 percent so far this year. Additionally, it has a price-to-cash flow ratio of 0.21 and its price-to-sales ratio stands at 0.07.
Currently, 7.20% of Elevate Credit‘s shares are possessed by insiders, while 38.00% of shares are possessed by financial institutions. Peterson David Curry, Chief Credit Officer of Elevate Credit Inc. (ELVT) sold 6,000 shares of firm against a total value of $100671.38 at the rate of 3.04 on Apr 07. Greever Scott, Chief Operating Officer of Elevate Credit Inc. (ELVT) sold 15,000 shares of the firm against a total value of $46050.0 at the rate of 3.07 on Mar 25. Harvison Jason, President, and CEO of Elevate Credit Inc. sold 14,000 shares of the firm against a total value of $50680.0 at the rate of 3.62 on Feb 08.
Galera Therapeutics Inc. (GRTX)
Galera Therapeutics Inc. (GRTX) is rising on the charts today, up 25.14% to trade at $2.19 at the last check in premarket trading. On Wednesday, shares in Galera Therapeutics Inc. rise 1.16% to close the day at $1.75. The volume of shares traded was 32478.0, which is lower than the average volume over the last three months of 122.01K. During the trading session, the stock oscillated between $1.6768 and $1.7799. The company had an earnings-per-share ratio of -2.35. GRTX’s stock has gained 5.42% of its value in the previous five sessions and 6.71% over the past month but has lost -61.87% on a year-to-date basis. The stock’s 50-day moving average of $1.6730 is above the 200-day moving average of $1.7309. Moreover, the stock is currently trading at an RSI of 58.85.
In October 19, 2021, several analysts downgraded their positions on the Galera Therapeutics Inc. stock and predicted its performance to their investors. The analysts at BTIG Research believe GRTX is still Neutral. Another analyst that has an Underperform rating for GRTX is BofA Securities, which set a price target of between $17 and $2. Credit Suisse resumed its Outperform position on the stock ($15) and Credit Suisse upgraded its Outperform position on the stock ($9 and $15).